Fritextsökning
Artiklar per år
Innehållstyper
-
Fler typer av fetma är farlig
Det är känt att ett brett midjemått kan knytas till risken för hjärtproblem. Nu visar en ny amerikansk studie att det finns fler kroppsdelar där tjockleken kan ställa till problem.
-
Storsatsning på ö-transplantation
En svensk studie kring transplantation av insulinproducerande celler stöttas med 130 miljoner kronor från amerikanska NIH.
-
Potatischips in i skamvrån igen
För sju år sedan kom de första larmen om höga halter akrylamid i chips och risk för cancer. Nu visar en ny polsk-svensk studie att den som äter för mycket chips löper ökad risk att drabbas av andra allvarliga sjukdomar.
-
Ingen koppling mellan akrylamid och bröstcancer
En stor amerikansk studie visar att den som äter mycket friterad mat inte löper högre risk att drabbas av bröstcancer än andra.
-
Nya rön kring blåbär och cancer
Möss som fick blåbärsextrakt fördubblade sin livslängd och hade hälften så stora tumörer som möss i en kontrollgrupp. Det visar en ny amerikansk studie.
-
Många miljoner till Symphogen
Ägarna skjuter till ett mångmiljonbelopp som ska användas till fortsatt klinisk utveckling av bolagets antikroppar mot bland annat cancer.
-
Ny skola for global hälsa
Sjukdom och hälsa i utvecklingsländer blir ett nytt insatsområde för Köpenhamns universitet. Idag invigs ett nytt centrum som bland annat ska arbeta med malaria och hiv.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
A smart company takes care of its best
Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
BREAKING